Functional Genomics PhD: Testing How Combinations of Genes Shape Human Cell Behaviour

Functional Genomics PhD: Testing How Combinations of Genes Shape Human Cell Behaviour

Quick Decision

This four-year MRC FGx-DLA project will adapt multiplexed Variable Dose Analysis (mVDA) from Drosophila to human cells. The method perturbs several genes at graded levels, allowing the team to test how combinations and dose interact. The student would validate the human-cell platform with known genetic interactions, then pair it with either live-cell imaging or single-cell sequencing. NF1 provides the disease-relevant proof of concept; the project does not promise a treatment or therapeutic result.

The fit is strongest for applicants who want method development across cell biology and quantitative analysis. The human-cell model, perturbation system, screen scale, readout and validation plan are not yet fixed in the public materials. Exeter lists 5 January 2027 as the current deadline, while an earlier notice lists 8 December 2026. Ask admissions to confirm the operative date and obtain written funding terms, especially for international tuition and the unpublished 2027/28 stipend.

Research Problem and Doctoral Work

What is unsolved and why it matters

Large sequencing studies link thousands of genetic variants to human traits and disease, but a variant's effect often depends on the genes and pathways around it. Genes rarely act alone: their combined activity can create a cellular phenotype that no single-gene experiment reveals. Standard CRISPR screens have made gene discovery far more scalable, yet testing dose-dependent effects and higher-order interactions remains difficult. Conventional combination screens can require increasingly large reagent libraries and cell numbers, and a single knockout may hide partial knockdown, buffering or synergistic effects.

The proposed approach is multiplexed Variable Dose Analysis (mVDA). The project says preliminary work has detected genetic interactions and linked mVDA to single-cell sequencing in Drosophila cells. It proposes to carry that approach into human cells. This is the core scientific risk as well as the project's main opportunity: human cells may differ in perturbation delivery, knockdown range, growth, phenotype and assay behavior. The project PDF does not specify the human cell type, the NF1 model, the exact mVDA reagents, or how success will be defined.

Advertised work and possible research angles

The official project PDF sets out three objectives:

1. Adapt and optimise mVDA in human cells, using established control interactions. The method is intended to perturb several genes across a range of knockdown efficiencies so that dose-dependent and combination effects can be separated. The PDF does not say whether the human-cell version will use RNA interference, CRISPR interference, knockout or another perturbation system. The cited mVDA preprint uses shRNA-based variable-dose measurements in Drosophila cells; applicants should ask what will transfer and what must be redesigned.
2. Pair the platform with either live-cell microscopy or single-cell sequencing. Live imaging may capture sensitive cellular phenotypes; sequencing may scale to larger screens and profile molecular states. The description says the choice can reflect student interest but gives no selection criteria, sample-size plan, cost comparison or milestones. That choice will shape the project's biological question and data workload.
3. Use NF1-related interactions as a proof of concept. NF1 is a tumour-suppressor gene, and the project proposes to search for interacting genes and potential combination-therapy hypotheses. The stated goal is a screening proof of concept, not a validated treatment or clinical outcome.

Potential questions include whether variable-dose measurements recover known control interactions in human cells; how reliably reagent dose predicts perturbation strength; how to distinguish single-gene effects from pairwise or higher-order interactions; and how candidate hits reproduce across cell models. These are evidence-led directions for discussion, not extra promised project tasks. A credible analysis will need negative and positive controls, biological replicates, independent validation, explicit interaction scoring and correction for multiple testing. The exact model, sample scale, score and validation design are not supplied.

What recent work says about the method and NF1 rationale

The supervisor's 2024 mVDA preprint describes a Drosophila-cell approach that multiplexes variable-dose perturbations and estimates gene and gene-pair effects from pooled populations. It is a relevant technical starting point, but it remains a preprint and does not establish performance in human cells. Exeter-affiliated work from the group has used Drosophila screening and Variable Dose Analysis to investigate NF1-related vulnerabilities, including an autophagy-related target study. A 2026 cross-species study reports hTERT as an NF1 synthetic-lethal partner and preclinical AZT-related effects. Together, these papers show a path from screening to biological validation, but they do not define this PhD's reagent system or guarantee a therapeutic finding.

The wider field is moving toward larger combination libraries and richer readouts. A 2023 Cell Systems study paired single-cell imaging with machine learning to map interactions across more than 6,800 Drosophila genes. A 2024 Cas12a platform screened thousands of gene combinations in cancer cells; a 2025 dual-guide system describes a 100,136-pair library; and a 2025 human-organoid study combined CRISPR modalities with single-cell readouts. These methods differ from mVDA, but they show that scale, perturbation efficiency, phenotype selection and validation are central design constraints rather than implementation details.

School, Programme and Field Context

The University of Exeter is the named primary institution and degree-awarding university. The project PDF places the work in the Department of Clinical and Biomedical Sciences and names support from the Functional Genomics Screening Laboratory and the Living Systems Institute. Exeter offers an MPhil/PhD Clinical and Biomedical Sciences route, with research areas that include molecular genetics and data science/AI. The project documents do not name its exact registration code, campus or whether another school formally co-registers the student; confirm those details before submitting the application.

Exeter's REF 2021 Biological Sciences submission (UoA 5) was rated 41% 4-star and 49% 3-star. Clinical Medicine (UoA 1) was 45% and 48%, respectively. These are institution-wide subject profiles, not a rating of this lab or project. Exeter's overall QS World University Ranking was 136 in 2027 and its overall THE rank was equal 170 in 2026; these provide broad context, not a genomics-specific comparison. The Clinical and Biomedical Sciences department describes interdisciplinary genetics, functional genomics, target-identification and data-science work. LSI's facility pages list relevant tissue culture, live-cell imaging, cytomics, sequencing and image-analysis capabilities. The project itself also advertises access to high-throughput screening and single-cell methods, but ask which services and staff support are allocated to this studentship.

Supervisor and Lab Assessment

Professor Benjamin Housden is the named lead supervisor and the only supervisor explicitly identified in the project PDF. His Exeter profile describes developing more sensitive and higher-throughput genetic screens, molecular methods, automation and machine-learning approaches to analyse screen data. His group applies screening methods to disease and drug-target questions, including NF1. This is a close match to the project’s tool-development and proof-of-concept structure. The PDF does not specify co-supervisors, how laboratory and computational guidance will be shared, or who owns the imaging/sequencing decisions.

The advertised environment spans the Functional Genomics Screening Laboratory and LSI. Exeter's facility pages describe tissue culture, high-content analysis, live-cell microscopy, sequencing and cytomics; these capabilities complement the project, but general facility descriptions do not guarantee instrument time, experimental support or data-science staffing. Ask what resources are committed and how the first-year training is organized.

Recent important papers

• Sengupta and Housden (2024), mVDA preprint: proposes multidimensional variable-dose analysis for high-throughput gene-interaction mapping in Drosophila cells. It is the closest technical precedent, but is a preprint, and its model-system results do not validate human-cell performance.
• Stevens et al. (2025), NF1 autophagy study: combines NF1-related Drosophila screening with VDA validation and follow-up experiments. It supports the group's NF1 screening context; its cell and preclinical results are not clinical evidence.
• Stevens, Oltean and Housden (2026), cross-species NF1 study: reports hTERT as a synthetic-lethal partner and investigates AZT-related effects across human cell models and xenografts. It is a recent example of the lab's screen-to-validation path, not a specified treatment task for this PhD.

Funding, Application, and Living Cost

The award is for September/autumn 2027 entry and provides a four-year studentship; part-time study is also listed. Exeter award 6025 describes UK tuition fees, a UKRI-minimum stipend and up to £5,000 per year in research-training and support funds. The current UKRI minimum is £21,805 for 2026/27, with rates updated annually. Do not assume this is the confirmed 2027/28 amount.

There is a fee-wording difference between official pages. The Exeter award page states UK tuition fees. The current national FGx-DLA postgraduate page says international students at Exeter do not need to supplement UKRI funding for international tuition. The latter is the more explicit statement for the current national programme, but applicants should ask for confirmation in the written award offer and check whether fee increases are covered.

The current official Exeter programme and award pages show 5 January 2027 as the application deadline. Earlier public information linked to this project showed 8 December 2026; the current programme page is the stronger source, but the live portal should be checked and the application prepared early. The application has two required stages: submit the Exeter online form, then complete the FGx-DLA questionnaire using the applicant ID. You may rank up to three project preferences, but submit only one application. The listed documents include transcripts, a CV of no more than two pages, two references, and English-language evidence if applicable. Applicants must meet the 2:1/equivalent requirement in a relevant subject; listed areas include genetics, molecular biology, biomedical science, human biology, biochemistry, medicine, healthcare professions, bioinformatics, computer science and statistics. The typical IELTS requirement is 7.0 overall with no component below 6.5. The questionnaire asks about motivation and longer-term aspirations, an achievement, learning from research experience, and any use of generative AI. Shortlisted applicants must arrange for academic references to arrive seven days before interview.

Exeter's broad student budget estimate is £1,300–£2,000 per month. The £21,805 current stipend is approximately £1,817 per month, inside that range but not above its upper end. One listed 2026/27 postgraduate self-catered room costs £124.74 per week for 44 weeks; that is an accommodation example rather than a complete budget. Visa, immigration health surcharge, travel and initial relocation costs are not itemized as funded in the project materials, so plan for them separately and confirm any reimbursements.

Applicant Fit and Preparation

The formal entry criteria are set by the DLA and department; the project PDF adds no separate degree, coding-language or clinical-credential requirement. The project is intentionally flexible across technology development, computational analysis, network analysis and biological application. However, its first objective is human-cell platform adaptation, so applicants should be ready to engage with experimental cell biology even if they aim to emphasize computation later.

Useful preparation includes molecular genetics or cell biology; CRISPR/RNAi or other perturbation work; statistical modelling and interaction analysis; reproducible coding; microscopy/image analysis; and single-cell genomics. These are suggested ways to strengthen an application, not an additional checklist. A strong research example can show how you chose controls, assessed perturbation efficiency, handled replicates or batch effects, and revised an experiment when a result was not reproducible. Applicants from quantitative backgrounds can explain how they would connect a model to biological controls; laboratory-focused applicants can show interest in analysis and data quality.

The broad sector outlook supports transferable value in genomics, screening, data analysis and hybrid science/AI skills. Skills England's 2026 assessment and the government Life Sciences Jobs Plan discuss these needs, while warning that projected demand and the effects of AI are uncertain. Possible routes include academic functional-genomics research, biotech or pharmaceutical R&D, screening and assay development, bioinformatics, translational genomics and data-science roles. The programme's national network may broaden contacts and training, but does not guarantee a placement or job.

Next Actions and Questions to Verify

Before applying

1. Check the live portal for the 5 January 2027 deadline; retain 8 December as an earlier conflicting date and submit well ahead of either date.
2. Ask whether the award is registered as MPhil/PhD Clinical and Biomedical Sciences, which campus applies, and whether your subject and English evidence meet the exact criteria.
3. Ask the lead supervisor which human-cell perturbation modality, cell models and control interactions are planned, and whether the student's preferred route can be imaging, sequencing or computational analysis.
4. Request confirmation of the 2027/28 stipend, international-fee coverage and whether fee increases, visa/IHS or relocation costs are supported.

At interview

• Which NF1 cell type and phenotype will anchor the proof of concept? What interaction order and number of perturbation dimensions are feasible?
• How will dose and reagent-delivery independence be measured? Which positive and negative control interactions, biological replicates and orthogonal validations are planned?
• What criteria determine microscopy versus single-cell sequencing, and what would count as successful platform validation?
• Who will supervise experimental design, image/sequencing analysis and statistical network inference? Which LSI/FGSL instruments and staff support are reserved for the project?

Before accepting an offer

Obtain written confirmation of the degree route and campus, start and end dates, four-year funding, stipend rate and annual updates, international fee coverage, research-support allowance, data and facility access, supervision arrangements, and personal costs not covered by the award.

Evidence and Sources

Project, programme, and institution

• Official project description PDF
• Exeter MRC FGx-DLA award 6025
• Exeter MRC FGx-DLA programme
• National FGx-DLA postgraduate research and international-fee policy
• UKRI Doctoral Landscape Awards in Medical Research
• MPhil/PhD Clinical and Biomedical Sciences
• Clinical and Biomedical Sciences research themes
• Exeter rankings and league tables
• Exeter REF 2021 results

Supervisor, laboratory, and recent papers

• Benjamin Housden profile
• Living Systems Institute: Gene Expression and Genomics
• Living Systems Institute facilities
• Sengupta and Housden: mVDA preprint
• Stevens et al.: NF1 autophagy study
• Stevens, Oltean and Housden: cross-species NF1 study

Methods, costs, and career context

• Single-cell imaging and machine-learning genetic interaction network
• Multiplex Cas12a genetic-interaction screening
• Dual-guide CRISPR interaction-screening system
• CRISPR screening in primary human gastric organoids
• Dual-CRISPR and high-content flow-cytometry method
• UKRI studentship stipend and fee guidance
• Exeter student living-cost estimate, 2026/27
• Exeter postgraduate accommodation options and rents
• UK Student visa information
• Skills England life-sciences skills assessment, 2026
• UK Life Sciences Jobs Plan